<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03836352</url>
  </required_header>
  <id_info>
    <org_study_id>P1719-SUR-Z11</org_study_id>
    <secondary_id>Keynote 903</secondary_id>
    <nct_id>NCT03836352</nct_id>
  </id_info>
  <brief_title>Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide &amp; Pembrolizumab, in Subjects With Selected Advanced &amp; Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc. (IMV Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc. (IMV Inc.)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide
      with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 2 with safety lead-in study to assess the safety and efficacy of
      DPX-Survivac, low dose cyclophosphamide, and pembrolizumab combination therapy in subjects
      with selected advanced and recurrent solid tumours. Two ovarian cancer arms will be recruited
      and randomized in this study, one with and one without cyclophosphamide. All other cohorts
      will be single arm, receiving treatment with the triple combination.

      Up to 20 subjects, from any cohort, will be enrolled to assess the safety of study treatments
      before the study moves to the expansion phase. Once the safety lead-in is completed, the five
      cohorts will be expanded to recruit additional subjects following a Simon two stage design.
      Enrollment in the ovarian cancer cohort will be randomized 1:1 into two arms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy as measured by objective response rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using RECIST v1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the rate of adverse events</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Centrally evaluated using iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Approximately 24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Cell mediated immunology</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As measured by antigen specific immune response in peripheral blood</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in immune cell infiltration</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>As measured by multiplex immunohistochemistry</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Microsatellite Instability-High</condition>
  <arm_group>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Cyclophosphamide, Pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPX-Survivac, Pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SubQ injection (q9w)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PO (BID)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV Infusion (q3w)</description>
    <arm_group_label>Arm 1 (All cohorts)</arm_group_label>
    <arm_group_label>Arm 2 (Ovarian cohort only)</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects with advanced or metastatic solid tumours who have completed treatment with
             first line therapy:

               1. Epithelial ovarian, fallopian tube, or peritoneal cancer

               2. Hepatocellular carcinoma

               3. Non-small cell lung cancer

               4. Urothelial cancer

               5. Microsatellite instability high solid tumours, other than the above indications

          -  Radiologic and/or biochemical evidence of disease progression

          -  Completion of pre-treatment tumour biopsy

          -  Subjects with HCC, NSCLC, BlCa, or MSI-H subjects other than those with gastric or
             colorectal cancer must have evidence of survivin expression in their pre-treatment
             biopsy sample

          -  Must have measurable disease by RECIST v1.1

          -  Ambulatory with an ECOG 0-1

          -  Life expectancy â‰¥ 6 months

          -  Meet protocol-specified laboratory requirements

        Key Exclusion Criteria:

          -  Chemotherapy or immunotherapy within treatment within 28 days of start of study
             treatment

          -  Radiotherapy within treatment within 2 weeks of start of study treatment

          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent
             directed to another stimulatory or co-inhibitory T cell receptor where subject was
             discontinued from that treatment due to a Grade 3 or higher immune-related toxicity

          -  For NSCLC subjects: Known EGFR mutations or ALK rearrangements

          -  Prior receipt of survivin-based vaccine(s) and/or immunotherapies

          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma
             in situ, or controlled bladder cancer

          -  Clinical ascites or pleural fluid that cannot be managed

          -  Malignant bowel obstruction or recent history of bowel obstruction

          -  For OvCa, subjects with any single lesion greater than 5 cm

          -  Autoimmune disease requiring treatment within the last two years (except replacement
             therapy)

          -  Recent history of thyroiditis

          -  Any history of (non-infectious) pneumonitis that required steroid therapy or current
             pneumonitis

          -  Presence of a serious acute or chronic infection

          -  Active CNS metastases and/or carcinomatous meningitis

          -  GI condition that might limit absorption of oral agents

          -  Allogenic tissue/solid organ transplant

          -  Other serious intercurrent chronic or acute illness, including myocardial infarction
             or cerebrovascular event within 6 months

          -  Ongoing treatment with steroid therapy or other immunosuppressive

          -  Receipt of live attenuated vaccines

          -  Acute or chronic skin and/or microvascular disorders

          -  Edema or lymphedema in the lower limbs &gt; grade 2

          -  Severe hypersensitivity (â‰¥ Grade 3) to pembrolizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center: Samuel Oschin Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kari Kayser</last_name>
      <phone>310-967-0694</phone>
      <email>kari.kayser@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Gerges</last_name>
      <phone>772-408-5159</phone>
      <email>cgerges@hemoncfl.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Iannotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Hematology and Oncology</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gouri Deshpande</last_name>
      <phone>727-344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>gdeshpande@flhemonc.com</email>
    </contact>
    <contact_backup>
      <last_name>Gina Askar</last_name>
      <phone>(727)344-6569</phone>
      <phone_ext>1025</phone_ext>
      <email>gaskar@flhemonc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pratibha Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute: The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia G Cox</last_name>
      <phone>404-778-5569</phone>
      <email>lydia.g.cox@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Manali Bhave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Brown Graham Cancer Center:University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Schoenbachler</last_name>
      <phone>502-562-4673</phone>
      <email>Jennifer.Schoenbachler@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Rebecca Redman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Cancer Institute</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Scuderi</last_name>
      <phone>504-842-7693</phone>
      <email>heather.scuderi@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Marc Matrana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus St. Vincent Regional Cancer Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chimela Ohaji</last_name>
      <phone>505-913-8935</phone>
      <email>chimela.ohaji@stvin.org</email>
    </contact>
    <investigator>
      <last_name>Olivier Rixe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Winthrop Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Himmel</last_name>
      <phone>516-663-1216</phone>
      <email>Jennifer.Himmel@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Eva Chalas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Referral Office</last_name>
      <phone>972-566-3000</phone>
      <email>referral@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>James Strauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Osler Health System</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Henry Conter, MD</last_name>
      <phone>905-494-2120</phone>
      <phone_ext>57264</phone_ext>
      <email>Henry.Conter@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Henry Conter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Kinrade</last_name>
      <phone>905-387-9711</phone>
      <phone_ext>64402</phone_ext>
      <email>ykinrade@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Hal Hirte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Center</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liselle Chieverton</last_name>
      <phone>905-895-4521</phone>
      <phone_ext>2297</phone_ext>
      <email>lchieverton@southlakeregional.org</email>
    </contact>
    <investigator>
      <last_name>Shaqil Kassam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Femina Kanji</last_name>
      <phone>613-737-8899</phone>
      <email>Fekanji@ohri.ca</email>
    </contact>
    <investigator>
      <last_name>Rakesh Goel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilda Carvalhana</last_name>
      <phone>(416) 480-5000</phone>
      <phone_ext>87435</phone_ext>
      <email>Ilda.Carvalhana@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Doherty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Levac</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>13727</phone_ext>
      <email>xavier.levac.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taylor Grant</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>23982</phone_ext>
      <email>Taylor.Grant@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>Lucy Gilbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de QuÃ©bec-UniversitÃ© Laval</name>
      <address>
        <city>QuÃ©bec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maryse Gingras</last_name>
      <phone>418-691-5781</phone>
      <email>maryse.gingras@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Vincent Castonguay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2019</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T cell activation</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Ovarian</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Non-small Cell Lung</keyword>
  <keyword>Bladder</keyword>
  <keyword>Microsatellite Instability-High</keyword>
  <keyword>Survivin</keyword>
  <keyword>Anti-PD-1</keyword>
  <keyword>MK-3475</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

